Novonesis (Novozymes) A/S (NSIS-B) - Net Assets

Latest as of March 2026: Dkr10.92 Billion DKK ≈ $1.71 Billion USD

Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) has net assets worth Dkr10.92 Billion DKK (≈ $1.71 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr16.52 Billion ≈ $2.59 Billion USD) and total liabilities (Dkr5.60 Billion ≈ $876.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Novonesis (Novozymes) A/S (NSIS-B) strategic investment index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Dkr10.92 Billion
% of Total Assets	66.09%
Annual Growth Rate	4.16%
5-Year Change	-11.07%
10-Year Change	-7.58%
Growth Volatility	12.54

Novonesis (Novozymes) A/S - Net Assets Trend (2002–2025)

This chart illustrates how Novonesis (Novozymes) A/S's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Novonesis (Novozymes) A/S.

Annual Net Assets for Novonesis (Novozymes) A/S (2002–2025)

The table below shows the annual net assets of Novonesis (Novozymes) A/S from 2002 to 2025. Also explore Novonesis (Novozymes) A/S (NSIS-B) equity growth momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	Dkr10.86 Billion ≈ $1.70 Billion	-2.87%
2024-12-31	Dkr11.18 Billion ≈ $1.75 Billion	-22.12%
2023-12-31	Dkr14.35 Billion ≈ $2.25 Billion	+0.86%
2022-12-31	Dkr14.23 Billion ≈ $2.23 Billion	+16.57%
2021-12-31	Dkr12.21 Billion ≈ $1.91 Billion	+8.56%
2020-12-31	Dkr11.24 Billion ≈ $1.76 Billion	-2.06%
2019-12-31	Dkr11.48 Billion ≈ $1.80 Billion	+0.37%
2018-12-31	Dkr11.44 Billion ≈ $1.79 Billion	+1.52%
2017-12-31	Dkr11.27 Billion ≈ $1.76 Billion	-4.07%
2016-12-31	Dkr11.74 Billion ≈ $1.84 Billion	+1.31%
2015-12-31	Dkr11.59 Billion ≈ $1.81 Billion	+2.77%
2014-12-31	Dkr11.28 Billion ≈ $1.76 Billion	+1.93%
2013-12-31	Dkr11.07 Billion ≈ $1.73 Billion	+15.66%
2012-12-31	Dkr9.57 Billion ≈ $1.50 Billion	+8.43%
2011-12-31	Dkr8.82 Billion ≈ $1.38 Billion	+12.61%
2010-12-31	Dkr7.84 Billion ≈ $1.23 Billion	+33.93%
2009-12-31	Dkr5.85 Billion ≈ $915.43 Million	+30.72%
2008-12-31	Dkr4.48 Billion ≈ $700.30 Million	+22.06%
2007-12-31	Dkr3.67 Billion ≈ $573.73 Million	+8.08%
2006-12-31	Dkr3.39 Billion ≈ $530.86 Million	-10.57%
2005-12-31	Dkr3.79 Billion ≈ $593.60 Million	-2.52%
2004-12-31	Dkr3.89 Billion ≈ $608.93 Million	-6.78%
2003-12-31	Dkr4.17 Billion ≈ $653.21 Million	-1.72%
2002-12-31	Dkr4.25 Billion ≈ $664.63 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Novonesis (Novozymes) A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 203.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	Dkr11.16 Billion	102.79%
Common Stock	Dkr125.50 Million	1.16%
Other Comprehensive Income	Dkr-428.46 Million	-3.95%
Total Equity	Dkr10.86 Billion	100.00%

Novonesis (Novozymes) A/S Competitors by Market Cap

The table below lists competitors of Novonesis (Novozymes) A/S ranked by their market capitalization.

Company	Market Cap
Pembina Pipeline Corp TO:PPL	$28.16 Billion
DENSO CORP. ADR 4 F:DNOA	$28.19 Billion
Chunghwa Telecom Co. Ltd F:CHWD	$28.24 Billion
Bank Hapoalim TA:POLI	$28.24 Billion
FIRSTRAND ADR/ 10 RC -01 F:FSR	$28.13 Billion
Sunbelt Rentals Holdings, Inc. NYSE:SUNB	$28.12 Billion
DCI Indonesia Tbk PT JK:DCII	$28.08 Billion
Volkswagen AG XETRA:VOW	$28.01 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Novonesis (Novozymes) A/S's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 11,176,000,000 to 10,855,200,000, a change of -320,800,000 (-2.9%).
Net income of 583,158,123 contributed positively to equity growth.
Dividend payments of 402,700,000 reduced retained earnings.
Share repurchases of 99,900,000 reduced equity.
New share issuances of 44,000,000 increased equity.
Other comprehensive income decreased equity by 446,447,277.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Dkr583.16 Million	+5.37%
Dividends Paid	Dkr402.70 Million	-3.71%
Share Repurchases	Dkr99.90 Million	-0.92%
Share Issuances	Dkr44.00 Million	+0.41%
Other Comprehensive Income	Dkr-446.45 Million	-4.11%
Other Changes	Dkr1.09 Million	+0.01%
Total Change	Dkr-	-2.87%

Book Value vs Market Value Analysis

This analysis compares Novonesis (Novozymes) A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 18.75x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 38.93x to 18.75x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2002-12-31	Dkr11.20	Dkr435.90	x
2003-12-31	Dkr11.61	Dkr435.90	x
2004-12-31	Dkr10.96	Dkr435.90	x
2005-12-31	Dkr11.22	Dkr435.90	x
2006-12-31	Dkr10.41	Dkr435.90	x
2007-12-31	Dkr11.50	Dkr435.90	x
2008-12-31	Dkr14.17	Dkr435.90	x
2009-12-31	Dkr18.49	Dkr435.90	x
2010-12-31	Dkr24.50	Dkr435.90	x
2011-12-31	Dkr27.53	Dkr435.90	x
2012-12-31	Dkr30.02	Dkr435.90	x
2013-12-31	Dkr34.83	Dkr435.90	x
2014-12-31	Dkr35.77	Dkr435.90	x
2015-12-31	Dkr37.43	Dkr435.90	x
2016-12-31	Dkr38.70	Dkr435.90	x
2017-12-31	Dkr37.87	Dkr435.90	x
2018-12-31	Dkr39.08	Dkr435.90	x
2019-12-31	Dkr40.02	Dkr435.90	x
2020-12-31	Dkr39.83	Dkr435.90	x
2021-12-31	Dkr42.20	Dkr435.90	x
2022-12-31	Dkr49.64	Dkr435.90	x
2023-12-31	Dkr50.30	Dkr435.90	x
2024-12-31	Dkr24.32	Dkr435.90	x
2025-12-31	Dkr23.25	Dkr435.90	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Novonesis (Novozymes) A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 5.37%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 14.04%
• Asset Turnover: 0.25x
• Equity Multiplier: 1.51x
Recent ROE (5.37%) is below the historical average (20.15%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2002	15.93%	11.47%	0.68x	2.06x	Dkr240.80 Million
2003	17.87%	12.67%	0.76x	1.86x	Dkr323.70 Million
2004	20.72%	13.16%	0.84x	1.86x	Dkr410.20 Million
2005	22.89%	13.71%	0.86x	1.94x	Dkr484.90 Million
2006	9.68%	4.78%	0.85x	2.37x	Dkr-10.90 Million
2007	28.49%	14.01%	0.84x	2.43x	Dkr676.30 Million
2008	23.78%	13.04%	0.82x	2.22x	Dkr615.50 Million
2009	20.48%	14.13%	0.78x	1.87x	Dkr610.90 Million
2010	20.63%	16.60%	0.77x	1.61x	Dkr831.60 Million
2011	20.75%	17.39%	0.76x	1.57x	Dkr947.10 Million
2012	21.09%	17.94%	0.74x	1.58x	Dkr1.06 Billion
2013	19.90%	18.73%	0.71x	1.49x	Dkr1.09 Billion
2014	22.42%	20.27%	0.68x	1.64x	Dkr1.40 Billion
2015	24.38%	20.16%	0.79x	1.54x	Dkr1.67 Billion
2016	26.00%	21.57%	0.76x	1.59x	Dkr1.88 Billion
2017	27.71%	21.46%	0.79x	1.63x	Dkr1.99 Billion
2018	28.24%	22.42%	0.73x	1.72x	Dkr2.08 Billion
2019	27.50%	21.94%	0.70x	1.78x	Dkr2.01 Billion
2020	25.15%	20.16%	0.68x	1.83x	Dkr1.70 Billion
2021	26.60%	21.04%	0.60x	2.09x	Dkr1.96 Billion
2022	3.57%	20.94%	0.08x	2.02x	Dkr-890.34 Million
2023	21.64%	16.90%	0.63x	2.03x	Dkr1.63 Billion
2024	2.73%	7.98%	0.25x	1.36x	Dkr-812.04 Million
2025	5.37%	14.04%	0.25x	1.51x	Dkr-502.36 Million

Industry Comparison

This section compares Novonesis (Novozymes) A/S's net assets metrics with peer companies in the Specialty Chemicals industry.

Industry Context

Industry: Specialty Chemicals
Average net assets among peers: $331,643,000
Average return on equity (ROE) among peers: 13.07%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Novonesis (Novozymes) A/S (NSIS-B)	Dkr10.92 Billion	15.93%	0.51x	$28.13 Billion
Flügger group A/S (FLUG-B)	$773.30 Million	12.49%	0.45x	$144.40 Million
Hove AS (HOVE)	$16.03 Million	14.13%	1.83x	$28.64 Million
SP Group A/S (SPG)	$205.60 Million	12.60%	2.74x	$871.38 Million

About Novonesis (Novozymes) A/S

CO:NSIS-B Denmark Specialty Chemicals

Market Cap

$28.13 Billion

Dkr179.80 Billion DKK

Market Cap Rank

#957 Global

#7 in Denmark

Share Price

Dkr435.90

Change (1 day)

-0.16%

52-Week Range

Dkr342.00 - Dkr463.00

All Time High

Dkr508.57